GlobeNewswire: Assertio Therapeutics, Inc. Contains the last 10 of 194 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:41:31ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/11/2844134/0/en/Assertio-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=27970Assertio Reports Fourth Quarter and Full Year 2023 Financial Results2024-03-11T20:01:00Z<![CDATA[Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million]]>https://www.globenewswire.com/news-release/2024/02/29/2838387/0/en/Assertio-Holdings-Inc-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-11-2024.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 20242024-02-29T21:05:00Z<![CDATA[LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, today announced that it will release fourth quarter and full year 2023 financial results on Monday, March 11, 2024, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.]]>https://www.globenewswire.com/news-release/2024/01/05/2804911/0/en/Assertio-Holdings-Inc-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2024-01-05T23:56:17Z<![CDATA[LAKE FOREST, Ill., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that effective January 2, 2024, the Compensation Committee of the Company’s Board of Directors granted two newly-hired employee a total of 16,498 restricted stock units (“RSUs”) and 18,654 stock options (“options”).]]>https://www.globenewswire.com/news-release/2024/01/03/2803350/0/en/Assertio-Holdings-Inc-Announces-Leadership-Transition.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. Announces Leadership Transition2024-01-03T13:59:00Z<![CDATA[Dan Peisert Stepping Down as CEO]]>https://www.globenewswire.com/news-release/2023/11/14/2780007/0/en/Assertio-Holdings-Inc-Appoints-Sravan-Emany-to-Its-Board-of-Directors.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors2023-11-14T13:00:00Z<![CDATA[LAKE FOREST, Ill., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Sravan Emany has been appointed to the Company’s Board of Directors. As part of the appointment, Assertio has expanded its board to seven seats. Mr. Emany currently serves as the Chief Financial Officer of Ironwood Pharmaceuticals.]]>https://www.globenewswire.com/news-release/2023/11/08/2776658/0/en/Assertio-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=27970Assertio Reports Third Quarter 2023 Financial Results2023-11-08T21:01:00Z<![CDATA[Closed Spectrum Acquisition on July 31, 2023, which diversifies and extends portfolio duration Cash balance at September 30, 2023 of $76.9 million Announces Management Updates]]>https://www.globenewswire.com/news-release/2023/11/02/2772620/0/en/Assertio-Holdings-Inc-to-Release-Third-Quarter-2023-Financial-Results-on-November-8-2023.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 20232023-11-02T16:06:17Z<![CDATA[LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.]]>https://www.globenewswire.com/news-release/2023/10/06/2756319/0/en/Assertio-Holdings-Inc-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2023-10-06T20:30:00Z<![CDATA[LAKE FOREST, Ill., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective October 4, 2023, the Compensation Committee of the Company’s Board of Directors granted one newly-hired employee a total of 9,800 restricted stock units (“RSUs”) and 11,575 stock options (“options”).]]>https://www.globenewswire.com/news-release/2023/08/25/2732141/0/en/Assertio-Holdings-Inc-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2023-08-25T20:05:00Z<![CDATA[LAKE FOREST, Ill., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective August 21, 2023, the Compensation Committee of the Company’s Board of Directors granted one newly-hired employee a total of 11,585 restricted stock units (“RSUs”) and 12,745 stock options (“options”).]]>https://www.globenewswire.com/news-release/2023/08/08/2721213/0/en/Assertio-Holdings-Inc-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27970Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2023-08-08T20:45:00Z<![CDATA[LAKE FOREST, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective July 31, 2023, the Compensation Committee of the Company’s Board of Directors granted eight newly-hired employees a total of 82,341 restricted stock units (“RSUs”) and 92,591 stock options (“options”).]]>